

## Dementia of the Alzheimer Type

Jessica J. Jalbert<sup>1</sup>, Lori A. Daiello<sup>1,2</sup>, and Kate L. Lapane<sup>1</sup>

<sup>1</sup> Department of Community Health – Epidemiology, Warren Alpert School of Medicine at Brown University, Providence, RI.

<sup>2</sup> Alzheimer's Disease and Memory Disorders Center, Rhode Island Hospital, Providence, RI.

Accepted for publication May 12, 2008.

Dementia of the Alzheimer type is a progressive, fatal neurodegenerative condition characterized by deterioration in cognition and memory, progressive impairment in the ability to carry out activities of daily living, and a number of neuropsychiatric symptoms. This narrative review summarizes the literature regarding descriptive epidemiology, clinical course, and characteristic neuropathological changes of dementia of the Alzheimer type. Although there are no definitive imaging or laboratory tests, except for brain biopsy, for diagnosis, brief screening instruments and neuropsychiatric test batteries used to assess the disease are discussed. Insufficient evidence exists for the use of biomarkers in clinical practice for diagnosis or disease management, but promising discoveries are summarized. Optimal treatment requires both nonpharmacological and pharmacological interventions, yet none have been shown to modify the disease's clinical course. This review describes the current available options and summarizes promising new avenues for treatment. Issues related to the care of persons with dementia of the Alzheimer type, including caregiver burden, long-term care, and the proliferation of dementia special care units, are discussed. Although advances have been made, more research is needed to address the gaps in our understanding of the disease.

Alzheimer disease; dementia; drug therapy; review

Abbreviations: APOE, apolipoprotein E; DAT, dementia of the Alzheimer type; DSM-IV-TR, *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition text revision; MMSE, Mini-Mental State Examination; NINCDS/ADRDA, National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association.

### INTRODUCTION

Dementia of the Alzheimer type (DAT) is a progressive, fatal neurodegenerative condition characterized by deterioration in cognition and memory, progressive impairment in the ability to carry out activities of daily living, and a number of neuropsychiatric and behavioral symptoms (1). DAT is the most common form of dementia among elderly persons and accounts for approximately two thirds of cases of dementia and between 60 percent and 70 percent of cases of progressive cognitive impairment in older adults (2, 3). The prevalence of DAT is expected to increase as the population ages (1).

In 2000, approximately 4.5 million people in the United States were living with DAT; by 2050, more than 13 million older Americans are projected to be afflicted with the con-

dition if current trends persist and no preventive treatments become available (4). The cognitive, behavioral, and functional decline in patients with DAT places a considerable burden on the health care system and caregivers (5). DAT is therefore a growing medical, social, and economic problem.

Despite the urgency of the situation, many questions remain unanswered in DAT research. For instance, although advanced age, female gender, carrying the apolipoprotein E (APOE)  $\epsilon 4$  allele, current smoking, family history of DAT or other dementia, fewer years of formal education, lower income, and lower occupational status have been associated with an increased risk of developing the condition, the pathogenesis of Alzheimer's disease is still largely unknown (6–8). Although progress is being made in developing new therapies for DAT, no therapeutic interventions to cure or substantially modify disease progression currently exist.

Correspondence to Jessica J. Jalbert, Department of Community Health – Epidemiology, Warren Alpert School of Medicine at Brown University, 121 South Main, Box G, Providence, RI 02912 (e-mail: Jessica\_Jalbert@brown.edu).

This review provides an update on the current state of knowledge on DAT. With a focus on findings generated from studies conducted in the United States, it describes the epidemiology of DAT, its characteristic clinical course, neuropsychiatric symptoms, factors associated with accelerated cognitive decline, characteristic neuropathological changes of Alzheimer's disease, diagnostic tools to assess DAT, and biomarkers and neuroimaging, and it provides an overview of pharmacological and nonpharmacological treatments. We also summarize the ramifications of DAT for caregivers and discuss long-term care.

## DEFINITIONS

The following definitions were adapted from the position statement of the American Association for Geriatric Psychiatry (9):

*Dementia* is a clinical syndrome characterized by global cognitive decline with memory and one other area of cognition affected that interfere significantly with the person's ability to perform the tasks of daily life and meet the *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition text revision (DSM-IV-TR) criteria.

*Dementia resulting from Alzheimer's disease or DAT* is characterized by decline primarily in cortical aspects of cognition (i.e., memory, language, praxis) and follows a characteristic time course of gradual onset and progression.

*Alzheimer's disease* is a specific degenerative brain disease characterized by senile plaques, neuritic tangles, and progressive loss of neurons, the presumptive cause of Alzheimer's disease.

## GLOBAL INCIDENCE AND PREVALENCE OF DAT

Data documenting the incidence of DAT indicate that it is a global problem that will become more severe as the population ages. Table 1 summarizes population-based studies estimating the incidence and prevalence of DAT. Studies from different parts of the world (North America, Europe, Asia, and Africa) were selected if they were population based and large. The estimates from the Delphi Consensus Study are for dementia rather than DAT but were included because prevalence/incidence estimates were generated from a systematic review of population-based studies. Regardless of country of origin, age-specific incidence rates of DAT increase exponentially with advancing age. In the United States, the incidence rate of DAT is 1 per 1,000 person-years among individuals aged 60–64 years and 25 per 1,000 person-years among those older than age 85 years (10). Although DAT is not a normal part of the aging process, the prevalence of DAT also increases with advancing age. While less than 1 percent of individuals aged 60–64 years are deemed to be affected, it is estimated that up to 40 percent of those over the age of 85 years have the condition (11). Similar trends were observed in a population-based European study of persons aged 65 years or older. The age-standardized prevalence of DAT was 4.4 percent, and the prevalence increased with age (0.6 percent for those aged 65–69 years; 22.2 percent for those aged 90 years or older) (12).

In the United States, 12 percent of the population is at least 65 years of age (13). By 2020, 16 percent of the population will be 65 years of age or older, and adults over 80 years of age are expected to account for 3.7 percent of the population (14, 15). Growth will occur in all racial and ethnic groups (4). By 2050, the number of persons with DAT is expected to increase to 13.2 million, and it is estimated that more than 8.0 million cases will be older than age 85 years (4).

## NEUROPSYCHIATRIC SYMPTOMS

Patients with DAT are likely to exhibit neuropsychiatric symptoms, also commonly referred to in the literature as behavioral and psychological symptoms of dementia, such as aggression/agitation, depression, apathy, anxiety, delusions, and hallucinations at some point during the course of the illness. Neuropsychiatric symptoms are common in all stages of dementia with prevalence estimates between 60 percent and 80 percent, depending on whether patients are community dwelling or institutionalized, and a lifetime risk of nearly 100 percent (16–20). The prevalence of neuropsychiatric symptoms in persons with DAT or dementia is greater than the background prevalence in the general population (16, 17, 21–24). Those symptoms most commonly seen in patients with DAT or dementia are apathy, depression, anxiety, aggression/agitation, and psychosis (delusions and hallucinations). The prevalence of apathy ranges from 20 percent to 51 percent and the 5-year prevalence is estimated as 71 percent (16, 18, 21, 23); the respective prevalences are 15–54 percent and 77 percent for depression (16, 18, 21, 22, 24–27) and 10–59 percent and 62 percent for anxiety (16, 18, 21, 23, 28). The prevalence estimates for aggression/agitation and psychosis range from 13 percent to 30 percent and from 12 percent to 74 percent, respectively (16, 18, 21, 29, 30). The considerable variation in the prevalence estimates results from the different operational definitions of dementia and neuropsychiatric symptoms, the different types of dementia studied, and the heterogeneity of the study populations. Other less-common and less-studied neuropsychiatric symptoms include irritability, elation, disinhibition, wandering, and aberrant motor behavior.

Neuropsychiatric symptoms in DAT may be better captured by grouping individual symptoms into various clusters (20, 31–34). The motivation behind identifying symptom clusters is that they may form syndromes, with each DAT–neuropsychiatric symptom subtype having a different prevalence and time course as well as distinct biologic correlates and psychosocial determinants (32). If neuropsychiatric symptom clusters reflect differences in brain regions affected by the disease, pharmacological and nonpharmacological treatment opportunities could be optimized (20, 32). Neuropsychiatric symptoms in DAT may be classified into three groups: an affective syndrome, a psychotic syndrome, and other neuropsychiatric disturbances (20). Diagnostic criteria for DAT-associated affective disorder and DAT-associated psychotic disorder have been proposed (34). Other neuropsychiatric symptom classification systems, all of which have identified clusters of mood or psychotic neuropsychiatric symptoms, have also been advanced (17, 35–39).

## NEUROPATHOLOGICAL FEATURES OF ALZHEIMER'S DISEASE

Alzheimer's disease can be definitively diagnosed only at brain autopsy or biopsy, when neuritic plaques reach a certain number in the most severely affected regions of the neocortex (40, 41). More stringent research criteria require the presence of neuritic plaques and neurofibrillary tangles in the neocortex (42–44).

Neuritic plaques consist of a central core of beta-amyloid peptides clumped together with fibrils of beta-amyloid, dystrophic neurites, reactive astrocytes, phagocytic cells, and other proteins and protein fragments derived from degenerating cells or liberated from neurons (45, 46). The accumulation of beta-amyloid seen in Alzheimer's disease brains may be the result of faulty beta-amyloid clearance (47), cleaving of the amyloid precursor protein by enzymes to yield free beta-amyloid peptides (48), or overproduction of beta-amyloid peptides caused by mutations in the amyloid precursor protein or the presenilins (49–54) or in the presence of the *APOE*  $\epsilon 4$  genotype (55, 56). Beta-amyloid fibrils aggregate and neuritic plaques form, triggering a locally induced, non-immune-mediated, chronic inflammatory response involving microglial cell activation and stimulation of a cerebral acute-phase reaction (57) (figure 1). Activated microglial cells release potentially neurotoxic proinflammatory cytokines (e.g., interleukin-6), reactive oxygen and nitrogen species, and proteolytic enzymes that may exacerbate neuronal damage (58, 59). Beta-amyloid fibrils also appear to exert direct neurotoxic effects (60–62).

Oxidative stress resulting from free radical damage may also be caused when soluble, aggregated amyloid fibrils are inserted into neuronal membranes, inducing lipid peroxidation, protein oxidation, and formation of reactive oxygen and nitrogen species (63). *APOE* may, in  $\epsilon 4$  allele carriers, exacerbate oxidative stress through its association with the catabolism of polyunsaturated fatty acids (63). Oxidative stress results in loss of cell potential, accumulation of excitotoxic molecules, and decreased neuronal viability (61).

Healthy neurons have microtubules stabilized by the *tau* protein; in Alzheimer's disease, this protein is hyperphosphorylated and aggregates as paired helical filaments, causing the dissociation of microtubules and the formation of neurofibrillary tangles that result in neurotransmitter deficits and neuronal cell death (45, 64–66). Beta-amyloid deposits may accelerate the formation of neurofibrillary tangles in brain areas associated with Alzheimer's disease (67, 68). Declining cholinergic function (69–71), reductions in synaptic density (71, 72), and the loss of neurons (71, 73–75) are also consistent features of Alzheimer's disease.

## CHARACTERISTICS AND CLINICAL COURSE OF DAT

DAT is associated with increased mortality, but survival among those with the disease varies widely (76, 77). Estimates of mean survival time are hampered by lack of definitive onset-of-disease dates. In a study that followed persons with DAT for an average of 4 years, 54 percent were institutionalized and 49 percent died (78). Median survival is estimated at 11.8 years (standard deviation, 0.6) since

retrospectively determined symptom onset and 5.7 years (standard deviation, 0.1) from initial clinic presentation (79). Baseline level of cognition may not predict mortality, but mortality is strongly related to rate of cognitive decline (76). Indeed, the lack of effective predictors of the rate of deterioration extends to the earliest stages of dementia (80).

In the early clinical stage, deficits occur in episodic memory, verbal abilities, visuospatial functions, attention, and executive functions (81). Sensory-motor performance and procedural memory seem to be intact, and only slight impairment may be seen in primary memory (81). Cognitive decline stems from unfunctional to global deficits (81). Performance falls off rapidly in all areas of cognitive functioning, but abilities thought to be subserved by the medial and lateral temporal lobes (episodic and semantic memory, respectively) appear to be substantially more impaired than those abilities thought to be subserved by the frontal lobes (82). Yearly cognitive decline varies from a loss of 2.7–4.5 points on the Mini-Mental State Examination (MMSE), 1.8–4.2 points on the Blessed Dementia Scale, and 12–13 points on the Cambridge Cognitive Examination to a gain of 2.6–4.5 points on the Blessed Test of Information, Memory, and Concentration (83).

The presence of one or more *APOE*  $\epsilon 4$  alleles is a significant predictor of the incidence of delusions during the course of DAT (84). The frequency and intensity of neuropsychiatric symptoms may increase with declining cognitive function in patients with DAT (76, 85–87) or may simply be correlated with duration of disease (88). Curvilinear associations between dementia severity and neuropsychiatric symptoms such as forgetfulness and emotional and impulsive behaviors have been reported (89, 90). Consensus has yet to be reached on whether the prevalence of individual neuropsychiatric symptoms remains constant at all stages of dementia or whether it varies systematically depending on the stage of the disease (21, 30, 91–94).

Some DAT patients appear to have neuropsychological deficits more prominent in one domain than in other domains (95). Language impairment in DAT may be associated with two distinct neuropsychological abnormalities: 1) a lexical/semantic impairment unrelated to onset or 2) progression of symptoms and a syntactic impairment that may be associated with earlier onset and more rapid progression of dementia (96, 97). The annual decline in language composite score was approximately 0.71 standard units, which did not differ by gender (98).

## CORRELATES OF MORE RAPID COGNITIVE DECLINE IN DAT

Progressive cognitive decline is the principal clinical manifestation of DAT, and a faster rate of decline is strongly associated with mortality (76). The rates at which people decline, however, differ substantially between affected persons, are difficult to predict, and are still not well understood (76, 99).

The *APOE*  $\epsilon 4$  allele, a strong genetic risk factor for DAT, is associated with a greater risk of developing DAT (odds ratio = 14.9, 95 percent confidence interval: 10.8, 20.6 for persons

**TABLE 1. Summary of studies estimating incidence and prevalence of DAT\* and dementia**

Study	Population/study design	Measure of disease frequency
<i>Incidence studies</i>		
North America		
Canadian Study of Health and Aging, Canadian Study of Health and Aging Working Group (291)	Population-based Canadian cohort study of 5,432 community-dwelling and 210 institutionalized persons 65 years of age or older	Women 65–69 years of age: 1.4 per 1,000 person-years (95% CI*: 0.1, 3.3); men 65–69 years of age: 0; women 85 years of age or older: 49.0 per 1,000 person-years (95% CI: 40.7, 57.2); men 85 years of age or older: 44.2 per 1,000 person-years (95% CI: 31.0, 57.5); women all ages: 7.4 per 1,000 person-years (95% CI: 4.4, 10.4); men all ages: 5.9 per 1,000 person-years (95% CI: 2.0, 9.8)
Cache County Study, Miech et al. (292)	US population-based cohort study of 3,308 persons aged 65 years or older	68 years of age or less: 2.2 per 1,000 person-years; 84–86 years of age: 57.9 per 1,000 person-years; all ages: 16.8 per 1,000 person-years
Monongahela Valley Independent Elders Survey (MoVIES), Ganguli et al. (293)	US population-based cohort study of 1,298 rural persons aged 65 years or older	65–69 years of age: 2.1 per 1,000 person-years (95% CI: 0.6, 7.8); 90 years of age or older: 50.9 per 1,000 person-years (95% CI: 23.3, 111.0); all ages: 11.6 per 1,000 person-years (95% CI: 9.5, 14.2)
North America/Africa		
Hendrie et al. (294)	2,459 Yoruba residents of Ibadan, Nigeria, aged 65 years or older; 2,147 African Americans residing in Indianapolis, Indiana, aged 65 years or older	Annual age-standardized incidence rate of DAT: Nigeria: 1.15% (95% CI: 0.96, 1.35); Indiana: 2.52% (95% CI: 1.4, 3.64)
Europe		
Fratiglioni et al. (295)	Estimates of DAT incidence in persons 65 years of age or older obtained by pooling population-based data from European population-based studies	65–69 years of age: 1.2 per 1,000 person-years (95% CI: 0.6, 2.3); over 90 years of age: 53.5 per 1,000 person-years (95% CI: 36.5, 55.8)
Neurologic Disorders in Central Spain Survey, Bermejo-Pareja et al. (296)	Population-based Spanish survey of 3,891 persons aged 65–90 years	65–69 years of age: 1.5 per 1,000 person-years (95% CI: 0.3, 4.4); 90 years of age or older: 52.6 per 1,000 person-years (95% CI: 31.7, 82.2); age-adjusted incidence rate: 7.4 per 1,000 person-years (95% CI: 6.0, 8.8)
Conselice Study of Brain Imaging, Ravaglia et al. (297)	Italian prospective population-based study of 927 persons aged 65 years or older	65–74 years of age: 11.3 per 1,000 person-years (95% CI: 7.1, 17.9); 85–94 years of age: 75.8 per 1,000 person-years (95% CI: 49.4, 116.2); all ages: 23.8 per 1,000 person-years (95% CI: 17.3, 31.7)
Rotterdam Study, Ruitenberg et al. (298)	Population-based Dutch study of 7,046 persons aged 55 years or older	65–69 years of age: 1.3 per 1,000 person-years (95% CI: 0.7, 2.3); 85–89 years of age: 34.8 per 1,000 person-years (95% CI: 27.7, 43.9); all ages: 7.2 per 1,000 person-years (95% CI: 6.4, 8.1)
Asia		
Li et al. (299)	Chinese cohort of 1,593 persons aged 60 years or older residing in Beijing	All ages: 5.4 per 1,000 person-years
Indo-US Cross-National Dementia Epidemiology Study, Chandra et al. (300)	Population-based Indian study of 5,126 persons aged 55 years or older	65–74 years of age: 1.2 per 1,000 person-years (95% CI: 0.25, 3.57); 85 years of age or older: 24.8 per 1,000 person-years (95% CI: 5.1, 72.5); 65 years of age or older: 3.24 per 1,000 person-years (95% CI: 1.48, 6.14)

Table continues

homozygous for the  $\epsilon 4$  genotype; persons with only one copy of  $\epsilon 4$  are also at increased risk—odds ratio = 2.6, 95 percent confidence interval: 1.6, 4.0 for those with an  $\epsilon 2/\epsilon 4$  genotype; odds ratio = 3.2, 95 percent confidence interval: 2.8, 3.8 for those with an  $\epsilon 3/\epsilon 4$  genotype, relative to persons with an  $\epsilon 3/\epsilon 3$  genotype) (100). Earlier age at onset is observed in a dose-dependent fashion (the average age at onset for persons with genotype  $\epsilon 4/\epsilon 4$ , only one  $\epsilon 4$  allele, and no  $\epsilon 4$  allele is 68 years, 76 years, and 84 years, respectively) (101). These findings have led to the hypothesis that *APOE*  $\epsilon 4$  allele carriers may experience a more rapid degenerative

process regarding development of DAT and that cognitive decline should progress more rapidly in these patients (102), but studies have provided conflicting evidence on whether the *APOE*  $\epsilon 4$  allele is associated with an accelerated rate of cognitive decline (102–107).

High educational attainment is also associated with an accelerated rate of cognitive deterioration in DAT patients (108, 109), and the cognitive reserve hypothesis has been proposed to explain this association. For instance, someone with a higher number of neuronal synapses or neurons could withstand a higher degree of neuropathological change

TABLE 1. Continued


Study	Population/study design	Measure of disease frequency
<b>World estimates</b>		
Delphi Consensus Study, Ferri et al. (301)	Estimates of annual incidence of dementia (per 1,000) in persons 60 years of age or older derived by using the Delphi consensus approach and guided by a systematic review of published work	North America: 10.5; Latin America: 9.2; western Europe: 8.8; eastern Europe: 7.7–8.1; North Africa and Middle Eastern Crescent: 7.6; Africa: 3.5; India and south Asia: 4.3; Indonesia, Thailand, and Sri Lanka: 5.9; China and developing western Pacific: 8.0; developed western Pacific: 7.0; world annual incidence: 7.5
<i>Prevalence studies</i>		
<b>North America</b>		
Health and Retirement Study, Plassman et al. (302)	Nationally representative sample of the US population ( <i>N</i> = 856) aged 71 years or older	71–79 years of age: 5.0%; 90 years of age or older: 37.4%; all ages: 9.7%
Framingham Study, Bachman et al. (303)	US population-based cohort study	Men: 1.17%; women: 3.01%
<b>North America/Africa</b>		
Hendrie et al. (304)	2,494 Yoruba residents of Ibadan, Nigeria, aged 65 years or older; 2,212 African Americans residing in Indianapolis, Indiana, aged 65 years or older	Age-adjusted prevalence in Nigeria: 1.41%; age-adjusted prevalence in Indiana for community-dwelling persons: 3.69%; age-adjusted prevalence in Indiana for persons living in the community and in nursing homes: 6.24%
<b>Africa</b>		
Farrag et al. (305)	Population-based Egyptian study of persons older than age 60 years	4.5% (95% CI: 3.6, 5.4)
<b>Europe</b>		
Lobo et al. (12)	Prevalence estimate for DAT in persons 65 years of age or older obtained by pooling population-based data from European population-based studies	Age-standardized prevalence: 4.4%; 65–69 years of age: 0.6%; 90 years of age or older: 22.2%
Rotterdam Study, Ott et al. (306)	Population-based study of Dutch persons aged 55 years or older	55–64 years of age: 0.20%; 85 years of age or older: 26.8%; all ages: 4.5%
<b>Asia</b>		
Gurvit et al. (307)	Population-based Turkish study of persons older than age 70 years	11.0% (95% CI: 7.0, 15.0)
Dong et al. (308)	Estimate of prevalence of DAT in China among persons aged 60 years or older derived from systematic analysis of work published between 1980 and 2004	1.6% (95% CI: 1.0, 2.7)
Zhang et al. (309)	Prevalence of DAT among persons 65 years of age or older across four regions in China: Beijing, Xian, Shanghai, Chengdu	4.8%
<b>World estimates</b>		
Delphi Consensus Study, Ferri et al. (301)	Estimates of prevalence of dementia in persons 60 years of age or older derived by using the Delphi consensus approach and guided by a systematic review of published work	North America: 6.4%; Latin America: 4.6%; western Europe: 5.4%; eastern Europe: 3.8%–3.9%; North Africa and Middle Eastern Crescent: 3.6%; Africa: 1.6%; India and south Asia: 1.9%; Indonesia, Thailand, and Sri Lanka: 2.7%; China and developing western Pacific: 4.0%; developed western Pacific: 4.3%; world prevalence 2001: 3.9%

\* DAT, dementia of the Alzheimer type; CI, confidence interval.

before becoming symptomatic (45, 109, 110). If patients with higher educational levels also have a higher cognitive reserve, then, when DAT symptoms become apparent, the pathological burden will already be more severe and widespread, and, with the cognitive reserve depleted, the patient would appear to experience cognitive decline at a more rapid rate (45, 109). Rapid cognitive decline has also been observed among patients exhibiting neuropsychiatric symp-

toms such as aggression/agitation, depression, psychosis, delusions, and hallucinations (30, 78, 111–113), but these findings have been challenged (114–118). The neurobiology underlying the emergence of neuropsychiatric symptoms is far from being understood, as is the mechanism by which these symptoms may accelerate cognitive decline (119–123).

Antipsychotic medications, widely used to treat neuropsychiatric symptoms (124, 125), have also been identified



**FIGURE 1.** Cascade of neuropathological events leading to the behavioral and cognitive features of dementia. Reproduced with permission from primary author J. L. Cummings and from *JAMA* 2002;287:2335–2338. Copyright © 2002, American Medical Association. All rights reserved.

as a factor accelerating cognitive decline (114, 126). Although it is possible that antipsychotics could exacerbate cognitive deficits through their anticholinergic effects (117), some studies have failed to corroborate the findings that antipsychotic medications are associated with more rapid cognitive decline in DAT patients (117, 127–129). Although there is little information on the effects of other commonly used psychotropic medications on cognition in patients with DAT (125, 129), a positive association between certain psychotropic medications (sedatives and anxiolytics) and cognitive deterioration has been reported (129).

## ASSESSMENT METHODS

In practice and in research, DAT is diagnosed by applying the DSM-IV-TR criteria (130) and/or those of the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) (40). Whereas the DSM-IV-TR criteria require the presence of memory impairment and cognitive deterioration in one other domain such as language, perception, or motor skills, or disturbances in executive functioning (130), the NINCDS/ADRDA criteria classify the likelihood of DAT into one of three categories: definite (clinical diagnosis coupled with a histologic confirmation of Alzheimer's disease), probable (clinical diagnosis without a histologic confirmation), and possible (atypical symptoms with no apparent alternative diagnosis in the absence of a histologic confirmation) (40). The NINCDS/ADRDA clinical diagnostic criteria, similar to those of the DSM-IV-TR, require a subtle onset and a gradual worsening of cognitive function and that other etiologies (e.g., thyroid diseases) be ruled out. Studies validating the NINCDS/ADRDA and DSM-IV-TR against a variety of "gold standards" have found that the sensitivity ranges from 65 percent

to 96 percent and that the specificity of these criteria for DAT against other dementia ranges from 23 percent to 88 percent (131–139).

Table 2 briefly summarizes the screening instruments used to determine the need for further evaluation. The MMSE (140), consisting of a brief assessment of language, memory, praxis, and orientation, is the most widely used and has been the most extensively studied with respect to its accuracy and validity (141–146). MMSE scores are affected by gender, educational attainment, age, and cultural background (143, 147, 148); the sensitivity of the MMSE is poor for patients with mild dementia (2, 149); the instrument is considered too time-consuming to administer in routine clinical practice (150, 151); not all changes in MMSE scores necessarily reflect true clinical improvement or decline (152, 153); and the MMSE exhibits floor effects in patients with severe impairment and ceiling effects in those who are mildly impaired (154). Modifications, alternatives, and supplements to the MMSE such as the modified version of the MMSE (155); the Montreal Cognitive Assessment (156); the Memory Impairment Screen (157); the Blessed Test of Information, Memory, and Concentration (158) and its abridged version, the Short Blessed Test (159); the One-Minute Verbal Fluency Test for Animals; and the Clock Drawing Test (160) have been advanced.

Although the lines between screening instruments and neuropsychological battery tests are sometimes blurred, generally the former are much less time-consuming and detailed than the latter; battery tests often combine multiple screening tests so that more cognitive symptoms in DAT can be covered in one assessment; and battery tests may allow for discrimination between DAT and other illnesses affecting cognitive function. One of the most commonly used neuropsychological instruments in clinical trials of anti-dementia medications in the United States is the Alzheimer's Disease Assessment Scale-Cognitive Subscale (161, 162).

**TABLE 2. Summary of commonly used DAT\* screening instruments**

Instrument	Cognitive domains assessed	Advantages	Disadvantages
MMSE* (140)	Language, memory, praxis, orientation	8–13 minutes in duration (310), covers a wide variety of cognitive domains in a brief test, reliable (149, 311)	Sensitivity poor in those with mild dementia (2, 149); performance affected by age, educational attainment, gender, and cultural background (2, 143, 148); too long to administer routinely in clinical practice (150, 151); ceiling effects in mild impairment and floor effects in severe impairment (154)
Modified MMSE (155)	Language, memory, praxis, orientation, executive functioning, visuospatial abilities	10–15 minutes in duration (310), samples a broader variety of cognitive domains than the MMSE (155), enhanced reliability and validity relative to the MMSE (155, 312)	Takes longer to administer than the MMSE
Montreal Cognitive Assessment (156)	Language, memory, praxis, orientation, visuospatial abilities, attention, concentration, executive functioning	High specificity and sensitivity for mild cognitive impairment and mild DAT (156), can detect mild cognitive impairment (156), reliable (156)	Useful primarily for mild cognitive impairment and mild DAT (156), longer to administer than the MMSE (156)
Memory Impairment Screen (157)	Memory	4 minutes in duration (310); performance not affected by age, education, or gender (313)	Covers few cognitive domains in DAT patients, sensitivity influenced by severity of dementia (157)
Blessed Test of Information, Memory, and Concentration (158)	Orientation, concentration, memory	Performance not correlated with educational background (151), does not require a specific form to administer	Covers few cognitive domains in DAT patients, demonstrates intermediate sensitivity (151)
Short Blessed Test (192)	Orientation, concentration, memory	5 minutes in duration (310), reliable (314, 315), can differentiate between mild cognitive impairment and normal subjects (159), highly sensitive and specific for dementia (313), high correlation with the MMSE (163, 314)	Covers few cognitive domains in DAT patients, should be used in conjunction with other screens
One-Minute Verbal Fluency Test For Animals	Language, semantic memory	1 minute in duration, less time-consuming than most screens, correlates well with the MMSE (163), demonstrates good discrimination between persons with dementia and normal controls (316), does not require a specific form to administer	Covers few cognitive domains in DAT patients, demonstrates intermediate sensitivity (151), should be used in conjunction with other screens
Clock Drawing Test	Praxis, executive functioning, attention, visuospatial abilities	2 minutes in duration (310), less time-consuming than most screens, high interrater reliability (317)	Covers few cognitive domains in DAT patients, subjective interpretation of clock drawing, intermediate sensitivity and specificity (313, 317), should be used in conjunction with other screens

\* DAT, dementia of the Alzheimer type; MMSE, Mini-Mental State Examination.

This instrument assesses memory, language, praxis, and orientation with a total score ranging from zero (no impairment) to 70 (severely impaired). The Neuropsychological Battery of the Consortium to Establish a Registry for Alzheimer's Disease (163) consists of seven tests, including the MMSE and three others adapted from the Alzheimer's Disease Assessment Scale-Cognitive Subscale (162) and measures memory, language, praxis, and orientation. Other neuropsychological tests used in dementia include, but are not limited to, the Syndrom-Kurztest (164) (assessing memory, attention, naming, and object arrangement), the Seven-Minute Neurocognitive Screening Battery (165) (assessing memory, orientation, visual abilities, praxis, and language skills), the Addenbrooke's Cognitive Examination (166) (assessing orientation, attention, memory, language, and visuospatial abilities), and the Cambridge Cognitive Examination (167) (assessing orientation, language, memory, praxis,

calculation, and perception). Screening instruments, particularly the MMSE, and more in-depth neuropsychological tests are also often used to chart the rate of cognitive decline.

## BIOMARKERS AND NEUROIMAGING

Disease-modifying drugs are likely to be more efficacious in the early or preclinical stage of the disease (168, 169). Promising biomarkers and neuroimaging could have a substantial public health impact if new drug candidates, such as beta-amyloid immunotherapy or beta-sheet breakers, were found to have disease-arresting effects (170). Evidence is currently insufficient to support or direct the use of biomarkers (table 3) in usual clinical practice for dementia diagnosis or disease management purposes.

**TABLE 3. Summary of the rationale and the disadvantages of selected CSF\* and plasma biomarkers**

Biomarker	Rationale	Disadvantages
CSF beta-amyloid	Decreased levels of beta-amyloid in CSF may reflect increased deposition of beta-amyloid in the brain (171).	Requires a lumbar puncture; invasive and uncomfortable procedure; despite availability of a commercial test with high sensitivity and specificity, this biomarker is underutilized (318).
CSF total <i>tau</i>	<i>tau</i> is released from dying neurons, so total <i>tau</i> concentration in the CSF is thought to reflect the intensity of the neuronal damage and degeneration (168).	Requires a lumbar puncture; invasive and uncomfortable procedure; nonspecific for Alzheimer's disease because elevated levels of <i>tau</i> are observed in other degenerative CNS* conditions (168); despite the availability of a commercial test with high sensitivity and specificity, this biomarker is underutilized (318).
CSF hyperphosphorylated <i>tau</i>	Concentration of phosphorylated <i>tau</i> in the CSF may reflect the formation of tangles in the brain because there is no increase in phosphorylated <i>tau</i> in other diseases with intense neuronal degeneration (e.g., Creutzfeldt-Jakob disease) (168).	Requires a lumbar puncture; invasive and uncomfortable procedure; despite the availability of a commercial test with high sensitivity and specificity, this biomarker is underutilized (318).
Plasma beta-amyloid	Beta-amyloid is produced in the brain and cleared to the plasma via the CSF and the blood brain barrier (319).	Plasma beta-amyloid levels do not correlate well with biochemical or pathological measures of cerebral beta-amyloid deposition (181); there is broad overlap in the plasma levels of beta-amyloid peptides in persons with DAT* and controls, making discrimination of persons with and without Alzheimer's disease difficult (171).
Plasma amyloid-beta autoantibodies	Antibodies against neuritic plaques may protect against Alzheimer's disease (320, 321).	Titer of beta-amyloid antibodies has been found to be significantly higher in healthy controls than in patients with DAT (322); some studies have found no correlation between antibody titer and prevalence of DAT (323); immune response to beta-amyloid 40 and tolerance of beta-amyloid 42 occurs naturally in humans and is not related to the neuritic plaque burden in the brain (171).
Plasma APOE*	The <i>APOE</i> $\epsilon$ 4 allele is associated with increased neuritic plaque load and elevated levels of beta-amyloid in the brain (324–326); the <i>APOE</i> $\epsilon$ 4 allele is associated with less APOE protein in plasma (327).	Studies of levels of APOE in DAT have been contradictory; some have reported elevated APOE levels in DAT (328), no difference (329–331), or reduced (332, 333) levels compared with controls.
Plasma isoprostanes	Increased levels of lipid oxidation in the Alzheimer's disease brain support a role for oxidative stress in DAT (171); free-radical-mediated peroxidation of polyunsaturated fatty acids creates isoprostanes (171).	Isoprostanes appear to be elevated in DAT patients relative to controls (334), but these findings have been challenged (335).
Inflammatory molecules such as interleukin-6	Amyloid deposition in the Alzheimer's disease brain elicits a range of inflammatory responses (57, 336); interleukin-6 is a cytokine implicated in inflammation.	Many of the proteins involved in the inflammatory response do not cross the blood-brain barrier (188); controversy exists regarding the levels of cytokine and acute-phase reaction reactants in the blood following an inflammatory response (187); findings from studies comparing the levels of plasma interleukin-6 in people with DAT and in healthy controls have been inconsistent (182, 185, 186, 337).

\* CSF, cerebrospinal fluid; CNS, central nervous system; DAT, dementia of the Alzheimer type; APOE, apolipoprotein E.

Beta-amyloid 42, a more aggregate-prone peptide derived from the amyloid precursor protein, a key molecule in Alzheimer's disease pathology (171), total *tau*, and phosphorylated *tau* in the cerebrospinal fluid are biomarkers with high diagnostic sensitivity and specificity for Alzheimer's disease (172, 173). The decrease in beta-amyloid 42 in the cerebrospinal fluid, presumably a result of its decreased clearance from the brain into the cerebrospinal fluid (174), has recently been added as one of the supportive features of the proposed revisions of NINCDS/ADRDA criteria for Alzheimer's disease (131). Cerebrospinal fluid biomarkers may be able to identify preclinical Alzheimer's disease even before the onset of mild cognitive impairment (175–177).

Plasma levels of beta-amyloid peptides in persons with DAT overlap those found in controls (171, 178–180) and do not reflect neuropathological or neurochemical measures of the levels of beta-amyloid deposition in the brain (181). Some studies reported increased levels of interleukin-6, a cytokine implicated in inflammation, in serum and plasma of persons with DAT (182, 183), whereas others did not (184–186). Cytokine and acute-phase-reaction reactant levels in the plasma or serum remain controversial (187), and many of these proteins do not cross the blood-brain barrier (188). Cerebrospinal fluid measures of beta-amyloid, total *tau*, and hyperphosphorylated *tau* are currently the best biomarkers available.



Within the medial temporal lobe, the disease consistently manifests itself through atrophy of the hippocampus and parahippocampal gyrus (189), which can be visualized by using structural magnetic resonance imaging (190). Magnetic resonance imaging measurements of the medial temporal lobe include the qualitative appraisal of atrophy in the hippocampal formation (191) as well as quantitative techniques analyzing tissue segmentation and computing cerebral volume (192). Sensitivity ranges from 80 percent to 100 percent (193–195) and specificity is over 90 percent (194) when magnetic resonance imaging–based estimates of the volume of various regions of the medial temporal lobe are used to discriminate between patients with Alzheimer’s disease and normal controls. Functional magnetic resonance imaging may also allow for earlier detection of Alzheimer’s disease (189).

Single-photon emission computed tomography has been used to measure regional cerebral blood flow, which correlates well with severity of DAT (196, 197) and prognosis (198), although its diagnostic accuracy for distinguishing between DAT and non-DAT in studies including healthy controls is quite low (pooled weighted sensitivities ranged from 65 percent to 71 percent with a specificity of 79 percent) (199). Computed tomography, the oldest technique for scanning the brain, is generally used to exclude other causes of dementia (e.g., subdural hematomas) (189) but is worse than cognitive screening in identifying dementia (200).

Positron emission tomography can assess hypometabolism and hypoperfusion and, when conducted with fluorodeoxyglucose, can measure the regional cerebral metabolic rate of glucose (201). Approved in the United States as a diagnostic tool, fluorodeoxyglucose–positron emission tomography is highly sensitive and specific in detecting Alzheimer’s disease in its early stages (202). Positron emission tomography techniques in combination with use of an amyloid-specific tracer may also provide *in vivo* visualization of neuritic plaques. Studies using the Pittsburgh Compound B, a molecule that binds preferentially to beta-amyloid fibrils (203), demonstrated that brains of DAT patients had a two- to threefold greater Pittsburgh Compound B retention on positron emission tomography scans relative to cognitively intact age-matched controls, and retention was consistent with Alzheimer’s disease pathology (204–206). Pittsburgh Compound B–positron emission tomography imaging of amyloid deposits may have the potential to increase diagnostic accuracy of DAT and could serve as a tool for monitoring the changes in beta-amyloid pathology over the course of DAT (206).

## TREATMENTS FOR DAT

Optimal treatment of DAT requires both nonpharmacological and pharmacological interventions (207). Given the progressive nature of the illness, interventions must be periodically reviewed and revised to meet the changing needs of the patient.

Nonpharmacological methods are appropriately used throughout the severity spectrum of DAT and are used alone or in combination with pharmacotherapy (208). Despite fre-

quent use in clinical practice, few have been studied in controlled trials. Much of the published evidence is characterized by a number of limitations such as inadequate sample sizes, short study duration, use of nonstandardized evaluation methods, and lack of information on persistence of treatment effects (209). Although short-term adverse consequences of nonpharmacological interventions, such as agitation and catastrophic reactions, have been reported in some studies, these outcomes have not been a focus of research (210).

The 2007 American Psychiatric Association guidelines for treatment of patients with DAT and other dementias categorize nonpharmacological or psychosocial treatments into four broad areas: emotion oriented (reminiscence therapy, validation therapy, supportive psychotherapy, sensory integration, and simulated-presence therapy), stimulation oriented (recreational activities, art therapies, exercise), cognition oriented (reality orientation, cognitive retraining, skills training), and behavior oriented (211). The growing interest in newer, nonpharmacological interventions such as cognitive rehabilitation and retraining techniques in the early stages of DAT is focused on developing therapies that enhance present capabilities and possibly augment the effects of cholinesterase inhibitors (212, 213). While some studies have reported treatment-related improvements in specific cognitive domains, well-designed, randomized trials of these interventions are lacking, and the effect on real-life skills, required for independent living, is largely unknown (214).

Nonpharmacological interventions for dementia-related neuropsychiatric symptoms have been more widely studied and target predominantly neuropsychiatric symptoms in mild to moderate stages of dementia (e.g., communication techniques, environmental alterations) (215). Studies of patient-centered behavioral interventions such as sensory stimulation or music therapy have reported positive, but short-lived effects on agitation and other symptoms (216). Caregiver interventions may have long-term benefits because several well-designed trials of psychoeducation programs for caregivers of persons with dementia reported a decrease in the frequency of neuropsychiatric symptoms and a delay in the time to institutionalization (217, 218).

The currently available DAT pharmacotherapeutic agents are symptomatic rather than disease-modifying treatments. Symptomatic treatments such as cholinesterase inhibitors and memantine, an *N*-methyl-*D*-aspartate receptor antagonist, may stabilize or slow the progression of DAT, but these effects are lost after discontinuation (219, 220). Disease-modifying therapies are being designed to target various aspects of DAT neuropathology and confer benefits that persist beyond the course of treatment. The three broad investigational classes of disease-modifying treatments are anti-amyloid agents, neuroprotective agents that reduce or protect against neuronal injury associated with amyloid deposition, and neurorestorative strategies such as nerve growth factors and cell transplantation (221). Experts in the field have theorized that the most effective DAT medication regimens of the future will combine symptomatic and disease-modifying agents (221, 222).

Cholinesterase inhibitors have been the cornerstone of contemporary DAT pharmacotherapy for over a decade and were developed based on the cholinergic hypothesis

of memory dysfunction (223). Degeneration of cholinergic neurons in the basal forebrain and declining levels of choline acetyltransferase, the enzyme responsible for acetylcholine synthesis, are associated with progressive decline of cholinergic transmission in the cerebral cortex and hippocampus (223). Cholinesterase inhibitors block the degradation of acetylcholine and are associated with modest benefits in the domains of cognition, function, and behavior in DAT clinical trials (224). Two drugs in this class, donepezil and galantamine, inhibit acetylcholinesterase, whereas tacrine and rivastigmine block both acetylcholinesterase and butyrylcholinesterase, an enzyme that plays a lesser role in the breakdown of acetylcholine (225). Galantamine is also an allosteric nicotinic receptor modulator and enhances the effect of acetylcholine on nicotinic receptors (226). Donepezil, rivastigmine, and galantamine have supplanted tacrine because of more convenient dosing, greater tolerability, and the absence of significant hepatotoxicity (224).

A recent meta-analysis of 13 double-blind, placebo-controlled trials using donepezil, rivastigmine, or galantamine treatments for 6 months to 1 year in patients with mild, moderate, or severe DAT reported improvements over placebo in cognition averaging 2.7 points (95 percent confidence interval:  $-3.0, -2.3$ ) on the 70-point Alzheimer's Disease Assessment Scale-Cognitive Subscale and 1.37 points (95 percent confidence interval: 1.13, 1.61) on the 30-point MMSE scale (227). Modest, but statistically significant benefits were also observed for global clinical ratings, activities of daily living functioning, and neuropsychiatric symptoms. More patients dropped out of cholinesterase inhibitor treatment groups because of adverse effects (29 percent) than placebo-treated patients (18 percent), and fewer patients experienced adverse events with donepezil compared with rivastigmine.

Despite the structural differences between various cholinesterase inhibitors, there is no evidence to suggest clinical differentiation in efficacy trials (227, 228). Of the four cholinesterase inhibitor comparative clinical trials that have been conducted, there is only one double-blind study: a 2-year comparison of donepezil with rivastigmine in patients with moderate DAT (range of MMSE scores: 10–20) (229). No significant treatment differences were observed between donepezil and rivastigmine regarding ratings of cognitive function, activities of daily living performance, and neuropsychiatric symptoms (229). However, compared with rivastigmine-treated patients, fewer donepezil patients discontinued treatment (odds ratio = 0.64, 95 percent confidence interval: 0.50, 0.83) (229).

More recently, dysregulation of glutamatergic neurotransmission in DAT was hypothesized to play a role in abnormal information processing, storage, and retrieval (230). Memantine, a low-to-moderate-affinity, noncompetitive, *N*-methyl-*D*-aspartate glutamate receptor antagonist, blocks excitotoxic neuronal toxicity associated with excessive release of glutamate (230). Memantine has been used in the treatment of a variety of neurologic disorders for more than 25 years in Europe and, in 2003, was approved in the United States to treat moderate-to-severe DAT.

Studies of memantine in patients with more advanced DAT have reported favorable treatment effects; randomized,

controlled trials of mild-moderate disease, however, have failed to show conclusive evidence of benefit (231, 232). In a 6-month, placebo-controlled, monotherapy trial, memantine was associated with improvements in cognition and function (233). In addition, memantine or placebo added to a stable regimen of donepezil resulted in significant treatment effects favoring memantine in cognitive, functional, neuropsychiatric, and global outcomes over a 6-month period (234). To our knowledge, no head-to-head trials comparing memantine monotherapy with cholinesterase inhibitors therapy in moderate-to-severe DAT have been conducted. Adverse-effect rates from placebo-controlled dementia trials indicate that memantine is generally well tolerated (233, 234).

Considerable debate over the value of the pharmacological treatment of DAT continues and is fueled by difficulties in translating the modest effects observed in controlled trials into meaningful clinical and economic benefits (235). The United Kingdom's National Institute for Health and Clinical Excellence recently revised its previous position and approved the use of cholinesterase inhibitors for moderate-stage DAT only (235). Memantine is not recommended as a treatment for DAT under the guidelines, except for patients participating in clinical trials. Without solid evidence to elucidate the optimal duration of therapy, the impact of treatment on outpatient and institutional caregiver burden, and the effects of therapy on patient and caregiver quality of life, payers will continue to question the utility of treating DAT with the currently available agents.

Another area of controversy in DAT pharmacotherapy is what constitutes appropriate treatment of neuropsychiatric symptoms. Pharmacological treatment of neuropsychiatric symptoms may be warranted when nonpharmacological interventions fail or when the nature or severity of neuropsychiatric symptoms endangers the safety of the patient or others (211). Before considering any pharmacological therapy to treat neuropsychiatric symptoms, it is essential that physiologic (hunger, thirst, need to void) and medical causes of the behavior be investigated and treated because these antecedents can trigger or exacerbate neuropsychiatric symptoms (236, 237).

Pharmacotherapeutic management of neuropsychiatric symptoms poses complex challenges for clinicians and caregivers because an increasing body of evidence has revealed that the potential "cost" in the form of adverse effects may offset marginal therapeutic benefits for many patients (238). A recent meta-analysis of antipsychotic, antidepressant, and anticonvulsant clinical trials for dementia-related neuropsychiatric symptoms concluded that these medications offer modest benefits and a considerable risk of adverse effects (239). No medication has been approved by the US Food and Drug Administration to treat dementia-related neuropsychiatric symptoms.

The second generation of antipsychotics, atypical antipsychotics, is the best-studied and most commonly prescribed class of psychoactive medications for neuropsychiatric symptoms. A number of recent placebo-controlled clinical trials of atypical antipsychotics for neuropsychiatric symptoms have reported small treatment effects coupled with adverse effects at rates that exceed those observed among placebo-treated

patients (238, 240). Results from some randomized controlled trials in dementia and subsequent meta-analyses have identified an increased risk of mortality and cerebrovascular-adverse events associated with atypical antipsychotic treatment (241, 242). Conventional antipsychotics may not be safer than atypical antipsychotics; subsequent analyses have reported an elevated risk of mortality associated with the use of older antipsychotics in patients with dementia and other psychiatric illnesses (243, 244). These developments have fueled an ongoing debate over the appropriate prescribing of antipsychotics (242, 245).

Better understanding of the safety issues associated with antipsychotic therapy and the lack of safer and more effective alternatives have stimulated interest in the effects of dementia-specific medication on neuropsychiatric symptoms. Modest reductions in neuropsychiatric symptoms have been reported from trials of cholinesterase inhibitors, memantine monotherapy, and combined memantine-donepezil in DAT patients (227, 246). Studies of small numbers of patients in open trials of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and in one double-blind, placebo-controlled trial with rivastigmine have reported varying degrees of improvement of neuropsychiatric symptoms and psychosis in dementia with Lewy bodies (247). Delusions, hallucinations, apathy, and agitation/aggression are the symptoms most likely to show significant improvement in trials of DAT or dementia with Lewy bodies (246), but there is considerable intertrial heterogeneity in neuropsychiatric symptoms domains showing the greatest response to treatment. Current treatment guidelines suggest a trial of a cholinesterase inhibitor and/or memantine in the management of nonacute neuropsychiatric symptoms (211, 239).

A substantial number of patients with dementia experience severe and persistent neuropsychiatric symptoms that may require the use of medication for varying periods of time throughout the course of DAT (248). The optimal treatment of neuropsychiatric symptoms is an essential research focus. More thoughtfully designed randomized controlled trials of pharmacological agents as monotherapy and in combination with innovative nonpharmacological interventions are urgently needed.

## CAREGIVING AND LONG-TERM CARE

As persons with DAT become more cognitively and functionally impaired, many lose the ability to care for themselves and become dependent on others for their care (249). The majority of informal DAT caregivers are caring for a relative, usually a parent, because the spouse of a DAT patient may be deceased or unable to provide the level of care needed without substantial help from his or her children (250, 251). The burden of care is often borne by one individual (252).

Caregiving generally requires a significant investment of time, energy, and money that often needs to be sustained over a period of years (252, 253). The number of hours per week spent providing care increases from 13.1 for patients with mild dementia to 46.1 for those in the more advanced

stage of the illness (254). Increasing dependency, personality changes, and neuropsychiatric symptoms such as aggression/agitation and depression are also highly distressing to the caregiver (255, 256). Providing assistance to a loved one afflicted with DAT comes at a considerable emotional, psychological, and physical cost to the caregiver. Informal caregivers report higher levels of depression and anxiety (255–259), lower overall life satisfaction (257, 260), and engaging in fewer preventive health behaviors (261), and they are at increased risk of illness (262–265) and mortality (266). Informal caregivers also often experience social isolation (256), financial strain (251, 259, 267), employment complications (258, 268), and disruption of relationships (258). Research has predominantly focused on the negative and deleterious aspects of caregiving, but some studies have found that caregivers of persons with dementia perceive their caregiving as providing them with positive and satisfying experiences (269–272).

The decision to institutionalize a loved one afflicted with DAT is difficult and complex but has been found to be associated with the patient's manifestation of neuropsychiatric symptoms, caregiver exhaustion, and the increased need for patient supervision (273–276). As many as 90 percent of patients with dementia will be institutionalized before death (277). Among new admissions to nursing homes, the prevalence of dementia is nearly 70 percent (278); in 1999, approximately 214,200 nursing home residents were living with DAT (279).

In the last few decades, there has been a rapid proliferation of dementia special care units in nursing homes (280). Approximately 10 percent of nursing homes had a special unit for people with dementia in the 1990s; this figure has risen to 20 percent (281, 282). There is no consensus definition of what constitutes "special care" for dementia, but a modified physical environment, special programs for residents and families, and additional staff training and coverage have become standard features (283). Studies evaluating the impact of living in a special care unit on improved resident outcomes (slower cognitive and functional decline and fewer neuropsychiatric symptoms) have been contradictory (284–287). In contrast, research has shown that the use of psychotropic medications is higher among residents of special care units (288–290).

## CONCLUSION

Alzheimer's disease is a complex neurodegenerative illness, but much progress has been made in understanding it. Research on the use of neuroimaging and biomarkers is promising and may allow for earlier and more accurate detection of Alzheimer's disease cases. Most studies across the world indicate that the incidence and prevalence of DAT are increasing. The majority of persons afflicted with DAT will exhibit neuropsychiatric symptoms, but symptom-specific prevalence estimates vary widely and it is unclear how and if stage-specific prevalence of individual symptoms changes. Current pharmacological treatments for DAT appear to slow progression of the disease but are not disease modifying. Further research on disease-modifying therapies

is needed if the prevalence and clinical course of the condition are to be altered. This review underscores that much more needs to be done before the mystery of DAT is unraveled.

## ACKNOWLEDGMENTS

The authors thank Dr. Andrea Gruneir for her help and guidance regarding the “Caregiving and Long-term Care” section of the manuscript.

Jessica J. Jalbert is a predoctoral fellow at Pfizer Inc. (New York, New York). This program is supported by a grant on which Kate L. Lapane is the principal investigator. Lori A. Daeillo has served as a consultant for Eli Lilly and Company (Indianapolis, Indiana), Forest Laboratories, Inc. (New York, New York), and Pfizer Inc.

## REFERENCES

- Cummings JL. Alzheimer's disease. *N Engl Med J* 2004;351:56–67.
- Cummings JL, Cole G. Alzheimer disease. *JAMA* 2002;287:2335–8.
- Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. *Neurology* 1998;51:728–33.
- Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Arch Neurol* 2003;60:1119–22.
- Sadik K, Wilcock G. The increasing burden of Alzheimer disease. *Alzheimer Dis Assoc Disord* 2003;17(suppl):S75–9.
- Reitz C, den Heijer T, van Duijn C, et al. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. *Neurology* 2007;69:998–1005.
- Huang W, Qiu C, von Strauss E, et al. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. *Arch Neurol* 2004;61:1930–4.
- Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. *European Studies of Dementia. Neurology* 1999;52:78–84.
- Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. *Am J Geriatr Psychiatry* 2006;14:561–72.
- van Duijn CM. Epidemiology of the dementias: recent developments and new approaches. *J Neurol Neurosurg Psychiatry* 1996;60:478–88.
- Breteler MM, Claus JJ, van Duijn CM, et al. Epidemiology of Alzheimer's disease. *Epidemiol Rev* 1992;14:59–82.
- Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. *Neurologic Diseases in the Elderly Research Group. Neurology* 2000;54(suppl):S4–9.
- Summary file 1. 2000 Census of population and housing. Washington, DC, US Census Bureau, 2007. (<http://www.census.gov/prod/cen2000/doc/sf1.pdf>).
- Health services research on aging: building on biomedical and clinical research. *Translating research into practice*. Rockville, MD: Agency for Healthcare Research and Quality, 2000. (Fact sheet; AHRQ publication no. 00-P012).
- Older Americans 2004: key indicators of well-being. Federal Interagency Forum on Aging-Related Statistics, 2004. ([http://www.agingstats.gov/agingstatsdotnet/Main\\_Site/Data/2004\\_Documents/entire\\_report.pdf](http://www.agingstats.gov/agingstatsdotnet/Main_Site/Data/2004_Documents/entire_report.pdf)).
- Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. *JAMA* 2002;288:1475–83.
- Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. *Neurology* 1996;46:130–5.
- Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. *Int J Geriatr Psychiatry* 2008;23:170–7.
- Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. *J Geriatr Psychiatry Neurol* 2007;20:41–9.
- Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. *Int J Geriatr Psychiatry* 2001;16:1043–53.
- Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. *Am J Psychiatry* 2000;157:708–14.
- McCormick WC, Kukull WA, van Belle G, et al. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. *J Am Geriatr Soc* 1994;42:517–21.
- Porter VR, Buxton WG, Fairbanks LA, et al. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. *J Neuropsychiatry Clin Neurosci* 2003;15:180–6.
- Zubenko GS, Zubenko WN, McPherson S, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. *Am J Psychiatry* 2003;160:857–66.
- Migliorelli R, Teson A, Sabe L, et al. Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease. *Am J Psychiatry* 1995;152:37–44.
- Vida S, Des Rosiers P, Carrier L, et al. Prevalence of depression in Alzheimer's disease and validity of Research Diagnostic Criteria. *J Geriatr Psychiatry Neurol* 1994;7:238–44.
- Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. III: disorders of mood. *Br J Psychiatry* 1990;157:81–6, 92–4.
- Landes AM, Sperry SD, Strauss ME. Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci* 2005;17:342–9.
- Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: disorders of behaviour. *Br J Psychiatry* 1990;157:86–94.
- Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. *Am J Psychiatry* 2005;162:2022–30.
- Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. *Am J Geriatr Psychiatry* 2000;8:29–34.
- Robert PH, Verhey FR, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical

- and biological aspects. Consensus paper of the European Alzheimer disease consortium. *Eur Psychiatry* 2005;20:490–6.
33. Olin JT, Katz IR, Meyers BS, et al. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. *Am J Geriatr Psychiatry* 2002;10:129–41.
  34. Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. *Int J Geriatr Psychiatry* 2001;16:1037–42.
  35. Aalten P, de Vugt ME, Lousberg R, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. *Dement Geriatr Cogn Disord* 2003;15:99–105.
  36. Cook SE, Miyahara S, Bacanu SA, et al. Psychotic symptoms in Alzheimer disease: evidence for subtypes. *Am J Geriatr Psychiatry* 2003;11:406–13.
  37. Tariot PN, Mack JL, Patterson MB, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. *Am J Psychiatry* 1995;152:1349–57.
  38. Frisoni GB, Rozzini L, Gozzetti A, et al. Behavioral syndromes in Alzheimer's disease: description and correlates. *Dement Geriatr Cogn Disord* 1999;10:130–8.
  39. Benoit M, Staccini P, Brocker P, et al. Behavioral and psychologic symptoms in Alzheimer's disease: results of the REAL.FR study. (In French). *Rev Med Interne* 2003;24(suppl):319s–24s.
  40. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939–44.
  41. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479–86.
  42. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. *Cereb Cortex* 1991;1:103–16.
  43. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. *Neurobiol Aging* 1997;18:S1–2.
  44. Jellinger KA, Bancher C. Proposals for re-evaluation of current autopsy criteria for the diagnosis of Alzheimer's disease. *Neurobiol Aging* 1997;18(suppl):S55–65.
  45. Cummings JL, Vinters HV, Cole GM, et al. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. *Neurology* 1998;51(suppl):S2–17, S65–7.
  46. Mann DM, Brown SM, Owen F, et al. Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. *Neuropathol Appl Neurobiol* 1998;24:187–94.
  47. Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. *J Cereb Blood Flow Metab* 2007;27:909–18.
  48. Nixon RA. Cell and molecular neuropathology of Alzheimer disease. In: Davis KL, Charney D, Coyle JT, et al, eds. *Neuropsychopharmacology: the fifth generation of progress*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:1221–9.
  49. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. *Nat Genet* 1992;1:345–7.
  50. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med* 1996;2:864–70.
  51. Sherrington R, Rogae EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 1995;375:754–60.
  52. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* 1998;391:387–90.
  53. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? *Proc Natl Acad Sci U S A* 1997;94:2095–7.
  54. Beyreuther K, Pollwein P, Multhaup G, et al. Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. *Ann N Y Acad Sci* 1993;695:91–102.
  55. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. *Nat Genet* 1997;17:263–4.
  56. Carter DB, Dunn E, McKinley DD, et al. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. *Ann Neurol* 2001;50:468–75.
  57. Eikelenboom P, Veerhuis R. The importance of inflammatory mechanisms for the development of Alzheimer's disease. *Exp Gerontol* 1999;34:453–61.
  58. Kalara RN. Microglia and Alzheimer's disease. *Curr Opin Hematol* 1999;6:15–24.
  59. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. *Brain Pathol* 1998;8:65–72.
  60. Pike CJ, Cummings BJ, Cotman CW. beta-Amyloid induces neuritic dystrophy in vitro: similarities with Alzheimer pathology. *Neuroreport* 1992;3:769–72.
  61. Varadarajan S, Yatin S, Aksenova M, et al. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. *J Struct Biol* 2000;130:184–208.
  62. Kowall NW, McKee AC, Yankner BA, et al. In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. *Neurobiol Aging* 1992;13:537–42.
  63. Butterfield DA, Drake J, Pocernich C, et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. *Trends Mol Med* 2001;7:548–54.
  64. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. *Nat Med* 1996;2:783–7.
  65. Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. *Neurology* 1998;51(suppl):S18–29, S65–7.
  66. Lee VM, Balin BJ, Otvos L Jr, et al. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. *Science* 1991;251:675–8.
  67. Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A beta 42 fibrils. *Science* 2001;293:1491–5.

68. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* 2001;293:1487–91.
69. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. *Brain Res* 1979;171:319–27.
70. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. *J Neurochem* 1995;64:749–60.
71. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J Neurol Neurosurg Psychiatry* 1999;66:137–47.
72. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. *Ann Neurol* 1990;27:457–64.
73. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. *Science* 1982;215:1237–9.
74. Mann DM. Pyramidal nerve cell loss in Alzheimer's disease. *Neurodegeneration* 1996;5:423–7.
75. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 1997;41:17–24.
76. Hui JS, Wilson RS, Bennett DA, et al. Rate of cognitive decline and mortality in Alzheimer's disease. *Neurology* 2003;61:1356–61.
77. Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer's disease and other dementia cases compared to controls: a population-based study. *J Clin Epidemiol* 2002;55:462–8.
78. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. *Arch Neurol* 2005;62:1601–8.
79. Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. *Neurology* 2005;65:719–25.
80. Storandt M, Grant EA, Miller JP, et al. Rates of progression in mild cognitive impairment and early Alzheimer's disease. *Neurology* 2002;59:1034–41.
81. Almkvist O. Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. *Acta Neurol Scand Suppl* 1996;165:63–71.
82. Mickes L, Wixted JT, Fennema-Notestine C, et al. Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. *Neuropsychology* 2007;21:696–705.
83. Aguero-Torres H, Fratiglioni L, Winblad B. Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project. *Int J Geriatr Psychiatry* 1998;13:755–66.
84. Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. *Neurology* 2002;58:1182–8.
85. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. *J Am Geriatr Soc* 1996;44:1078–81.
86. Teri L, Larson EB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer's type. *J Am Geriatr Soc* 1988;36:1–6.
87. Agniel A, Celsis P, Puel M, et al. Psychiatric disorders in dementia of Alzheimer type: cognitive and hemodynamic correlates. *Dementia* 1990;1:215–21.
88. Devanand DP, Brockington CD, Moody BJ, et al. Behavioral syndromes in Alzheimer's disease. *Int Psychogeriatr* 1992;4:161–84.
89. McCarty HJ, Roth DL, Goode KT, et al. Longitudinal course of behavioral problems during Alzheimer's disease: linear versus curvilinear patterns of decline. *J Gerontol A Biol Sci Med Sci* 2000;55:M200–6.
90. Mitnitski AB, Graham JE, Mogilner AJ, et al. The rate of decline in function in Alzheimer's disease and other dementias. *J Gerontol A Biol Sci Med Sci* 1999;54:M65–9.
91. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. *Neurology* 2000;54:1965–71.
92. Kuzis G, Sabe L, Tiberti C, et al. Neuropsychological correlates of apathy and depression in patients with dementia. *Neurology* 1999;52:1403–7.
93. Bierman EJ, Comijs HC, Jonker C, et al. Symptoms of anxiety and depression in the course of cognitive decline. *Dement Geriatr Cogn Disord* 2007;24:213–19.
94. Chen JC, Borson S, Scanlan JM. Stage-specific prevalence of behavioral symptoms in Alzheimer's disease in a multi-ethnic community sample. *Am J Geriatr Psychiatry* 2000;8:123–33.
95. Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. *J Neurol Neurosurg Psychiatry* 2007;78:917–28.
96. Rebok G, Brandt J, Folstein M. Longitudinal cognitive decline in patients with Alzheimer's disease. *J Geriatr Psychiatry Neurol* 1990;3:91–7.
97. Becker JT, Huff FJ, Nebes RD, et al. Neuropsychological function in Alzheimer's disease. Pattern of impairment and rates of progression. *Arch Neurol* 1988;45:263–8.
98. Hebert LE, Wilson RS, Gilley DW, et al. Decline of language among women and men with Alzheimer's disease. *J Gerontol B Psychol Sci Soc Sci* 2000;55:P354–60.
99. Wilson RS, Gilley DW, Bennett DA, et al. Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age. *Psychol Aging* 2000;15:18–28.
100. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* 1997;278:1349–56.
101. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993;261:921–3.
102. Hirono N, Hashimoto M, Yasuda M, et al. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. *J Neuropsychiatry Clin Neurosci* 2003;15:354–8.
103. Craft S, Teri L, Edland SD, et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. *Neurology* 1998;51:149–53.
104. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. *Ann Neurol* 1997;41:615–20.
105. Kleiman T, Zdanys K, Black B, et al. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. *Dement Geriatr Cogn Disord* 2006;22:73–82.
106. Jonker C, Schmand B, Lindeboom J, et al. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. *Arch Neurol* 1998;55:1065–9.

107. Slioter AJ, Houwing-Duistermaat JJ, van Harskamp F, et al. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. *J Neurol* 1999;246:304–8.
108. Wilson RS, Li Y, Aggarwal NT, et al. Education and the course of cognitive decline in Alzheimer disease. *Neurology* 2004;63:1198–202.
109. Scarmeas N, Albert SM, Manly JJ, et al. Education and rates of cognitive decline in incident Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2006;77:308–16.
110. Scarmeas N, Stern Y. Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease. *Curr Neurol Neurosci Rep* 2004;4:374–80.
111. Teri L, McCurry SM, Edland SD, et al. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. *J Gerontol A Biol Sci Med Sci* 1995;50:M49–55.
112. Wilson RS, Gilley DW, Bennett DA, et al. Hallucinations, delusions, and cognitive decline in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2000;69:172–7.
113. Bassuk SS, Berkman LF, Wypij D. Depressive symptomatology and incident cognitive decline in an elderly community sample. *Arch Gen Psychiatry* 1998;55:1073–81.
114. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. *BMJ* 1997;314:266–70.
115. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: disorders of thought content. *Br J Psychiatry* 1990;157:72–6, 92–4.
116. Lopez OL, Boller F, Becker JT, et al. Alzheimer's disease and depression: neuropsychological impairment and progression of the illness. *Am J Psychiatry* 1990;147:855–60.
117. Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. *Arch Neurol* 1999;56:1266–72.
118. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. *JAMA* 1997;277:806–12.
119. Mega MS, Lee L, Dinov ID, et al. Cerebral correlates of psychotic symptoms in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2000;69:167–71.
120. Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. *Arch Neurol* 1991;48:619–24.
121. Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. *Arch Gen Psychiatry* 2000;57:1165–73.
122. Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. *J Neuropsychiatry Clin Neurosci* 2001;13:5–21.
123. Herrmann N, Lanctot KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. *J Neuropsychiatry Clin Neurosci* 2004;16:261–76.
124. Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. *Pharmacotherapy* 1995;15:495–501.
125. Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. *J Clin Psychiatry* 2004;65:5–99, 100–2.
126. Ballard C, Margallo-Lana M, Juszcak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. *BMJ* 2005;330:874.
127. Livingston G, Walker AE, Katona CL, et al. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. *J Neurol Neurosurg Psychiatry* 2007;78:25–9.
128. Caballero J, Hitchcock M, Scharre D, et al. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. *Clin Ther* 2006;28:1695–700.
129. Ellul J, Archer N, Foy CM, et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. *J Neurol Neurosurg Psychiatry* 2007;78:233–9.
130. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000.
131. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol* 2007;6:734–46.
132. Kukull WA, Larson EB, Reifler BV, et al. The validity of 3 clinical diagnostic criteria for Alzheimer's disease. *Neurology* 1990;40:1364–9.
133. Blacker D, Albert MS, Bassett SS, et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. *Arch Neurol* 1994;51:1198–204.
134. Hogervorst E, Barnetson L, Jobst KA, et al. Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. *Dement Geriatr Cogn Disord* 2000;11:107–13.
135. Hogervorst E, Bandelow S, Combrinck M, et al. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. *Dement Geriatr Cogn Disord* 2003;16:170–80.
136. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. *J Am Geriatr Soc* 1999;47:564–9.
137. Petrovitch H, White LR, Ross GW, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. *Neurology* 2001;57:226–34.
138. Varma AR, Snowden JS, Lloyd JJ, et al. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. *J Neurol Neurosurg Psychiatry* 1999;66:184–8.
139. Kazee AM, Eskin TA, Lapham LW, et al. Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. *Alzheimer Dis Assoc Disord* 1993;7:152–64.
140. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. *J Psychiatr Res* 1975;12:189–98.
141. Aevansson O, Skoog I. A longitudinal population study of the mini-mental state examination in the very old: relation to dementia and education. *Dement Geriatr Cogn Disord* 2000;11:166–75.
142. Cossa FM, Sala SD, Musicco M, et al. The Milan overall dementia assessment and the mini-mental state examination compared: an epidemiological investigation of dementia. *Eur J Neurol* 1999;6:289–94.
143. Dufouil C, Clayton D, Brayne C, et al. Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-Mental State Examination. *Neurology* 2000;55:1609–13.

144. Flicker L, Logiudice D, Carlin JB, et al. The predictive value of dementia screening instruments in clinical populations. *Int J Geriatr Psychiatry* 1997;12:203–9.
145. Monsch AU, Foldi NS, Ermini-Funfschilling DE, et al. Improving the diagnostic accuracy of the Mini-Mental State Examination. *Acta Neurol Scand* 1995;92:145–50.
146. Tangalos EG, Smith GE, Ivnik RJ, et al. The Mini-Mental State Examination in general medical practice: clinical utility and acceptance. *Mayo Clin Proc* 1996;71:829–37.
147. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms for the Mini-Mental State Examination by age and educational level. *JAMA* 1993;269:2386–91.
148. Grigoletto F, Zappala G, Anderson DW, et al. Norms for the Mini-Mental State Examination in a healthy population. *Neurology* 1999;53:315–20.
149. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. *J Am Geriatr Soc* 1992; 40:922–35.
150. Boise L, Camicioli R, Morgan DL, et al. Diagnosing dementia: perspectives of primary care physicians. *Gerontologist* 1999;39:457–64.
151. Kilada S, Gamaldo A, Grant EA, et al. Brief screening tests for the diagnosis of dementia: comparison with the mini-mental state exam. *Alzheimer Dis Assoc Disord* 2005;19: 8–16.
152. Schmand B, Lindeboom J, Launer L, et al. What is a significant score change on the mini-mental state examination? *Int J Geriatr Psychiatry* 1995;10:411–14.
153. Tombaugh TN. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. *Arch Clin Neuropsychol* 2005;20:485–503.
154. Feher EP, Mahurin RK, Doody RS, et al. Establishing the limits of the Mini-Mental State Examination of 'subtests'. *Arch Neurol* 1992;49:87–92.
155. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. *J Clin Psychiatry* 1987;48:314–18.
156. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695–9.
157. Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the memory impairment screen. *Neurology* 1999;52:231–8.
158. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. *Br J Psychiatry* 1968;114:797–811.
159. Katzman R, Brown T, Fuld P, et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. *Am J Psychiatry* 1983;140:734–9.
160. Critchley M. The parietal lobes. New York, NY: Hafner, 1953.
161. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. *Am J Psychiatry* 1984;141:1356–64.
162. Mohs RC. Neuropsychological assessment of patients with Alzheimer's disease. In: *Psychopharmacology: the fourth generation of progress*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1994.
163. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology* 1989;39:1159–65.
164. Erzigkeit H. *Manual zum SKT Formen A-E (4. Auflage)*. (In German). Beltz, Weinheim, Germany, 1989.
165. Solomon PR, Hirschhoff A, Kelly B, et al. A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. *Arch Neurol* 1998;55:349–55.
166. Mathuranath PS, Nestor PJ, Berrios GE, et al. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. *Neurology* 2000;55:1613–20.
167. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. *Br J Psychiatry* 1986;149:698–709.
168. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. *Lancet Neurol* 2003;2:605–13.
169. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. *Science* 2003;302:830–4.
170. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurol* 2006;5:228–34.
171. Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. *Curr Opin Psychiatry* 2008;21:260–7.
172. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. *Arch Neurol* 2001;58: 373–9.
173. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. *Ann Neurol* 1998;44:17–26.
174. Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. *Neurology* 2008;70:596–606.
175. Skoog I, Davidsson P, Aevansson O, et al. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. *Dement Geriatr Cogn Disord* 2003;15:169–76.
176. Moonis M, Swearer JM, Dayaw MP, et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. *Neurology* 2005;65:323–5.
177. Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biol Psychiatry* 2004;56:670–6.
178. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. *Amyloid* 2000;7:245–58.
179. Kosaka T, Imagawa M, Seki K, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). *Neurology* 1997;48:741–5.
180. Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. *Arch Neurol* 2003;60:958–64.
181. Freeman SH, Raju S, Hyman BT, et al. Plasma A beta levels do not reflect brain A beta levels. *J Neuropathol Exp Neurol* 2007;66:264–71.
182. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? *J Neuroimmunol* 2000;103:97–102.
183. Kalman J, Juhasz A, Laird G, et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. *Acta Neurol Scand* 1997;96:236–40.
184. van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. *Neurosci Lett* 1990;108:350–4.



185. Angelis P, Scharf S, Mander A, et al. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. *Neurosci Lett* 1998;244:106–8.
186. Chao CC, Ala TA, Hu S, et al. Serum cytokine levels in patients with Alzheimer's disease. *Clin Diagn Lab Immunol* 1994;1:433–6.
187. Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. *J Alzheimers Dis* 2001;3:131–57.
188. Irizarry MC. Biomarkers of Alzheimer disease in plasma. *NeuroRx* 2004;1:226–34.
189. Scheltens P, Korff ES. Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. *Curr Opin Neurol* 2000;13:391–6.
190. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. *Neurology* 2002;58:750–7.
191. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry* 1992;55:967–72.
192. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. *Neurology* 1997;49:786–94.
193. Barber R, Gholkar A, Scheltens P, et al. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. *Neurology* 1999;52:1153–8.
194. Golebiowski M, Barcikowska M, Pfeffer A. Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type. *Dement Geriatr Cogn Disord* 1999;10:284–8.
195. Frisoni GB, Laakso MP, Beltramello A, et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. *Neurology* 1999;52:91–100.
196. Ashford JW, Shih WJ, Coupal J, et al. Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease. *J Nucl Med* 2000;41:57–64.
197. Rodriguez G, Nobili F, Copello F, et al. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study. *J Nucl Med* 1999;40:522–9.
198. Claus JJ, Walstra GJ, Hijdra A, et al. Measurement of temporal regional cerebral perfusion with single-photon emission tomography predicts rate of decline in language function and survival in early Alzheimer's disease. *Eur J Nucl Med* 1999;26:265–71.
199. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. *Am J Geriatr Psychiatry* 2004;12:554–70.
200. Chaves ML, Ilha D, Maia AL, et al. Diagnosing dementia and normal aging: clinical relevance of brain ratios and cognitive performance in a Brazilian sample. *Braz J Med Biol Res* 1999;32:1133–43.
201. Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. *NeuroRx* 2005;2:348–60.
202. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. *J Nucl Med* 2002;43:253–66.
203. Klunk WE, Engler H, Nordberg A, et al. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. *Neuroimaging Clin N Am* 2003;13:781–9.
204. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. *J Cereb Blood Flow Metab* 2005;25:1528–47.
205. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol* 2004;55:306–19.
206. Ikonomic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain* 2008;131:1630–45.
207. Rubin CD. The primary care of Alzheimer disease. *Am J Med Sci* 2006;332:314–33.
208. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001;56:1154–66.
209. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. *Am J Geriatr Psychiatry* 2001;9:361–81.
210. Dietch JT, Hewett LJ, Jones S. Adverse effects of reality orientation. *J Am Geriatr Soc* 1989;37:974–6.
211. APA Work Group on Alzheimer's Disease and Other Dementias, Rabins PV, Blacker D, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. *Am J Psychiatry* 2007 (suppl);164:5–56.
212. Requena C, Lopez Ibor MI, Maestu F, et al. Effects of cholinergic drugs and cognitive training on dementia. *Dement Geriatr Cogn Disord* 2004;18:50–4.
213. Matsuda O. Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. *Int Psychogeriatr* 2007;19:241–52.
214. Acevedo A, Loewenstein DA. Nonpharmacological cognitive interventions in aging and dementia. *J Geriatr Psychiatry Neurol* 2007;20:239–49.
215. Spira AP, Edelstein BA. Behavioral interventions for agitation in older adults with dementia: an evaluative review. *Int Psychogeriatr* 2006;18:195–225.
216. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. *Am J Psychiatry* 2005;162:1996–2021.
217. Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. *JAMA* 1996;276:1725–31.
218. Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. *Ann Intern Med* 2006;145:713–26.
219. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. *Arch Neurol* 2001;58:427–33.
220. Reisberg B, Doody R, Stoffer A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. *Arch Neurol* 2006;63:49–54.
221. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. *Neurology* 2007;69:1622–34.
222. Cummings JL. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. *Rev Neurol Dis* 2007;4:57–62.

223. Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. *J Clin Psychiatry* 2003;64:11–17.
224. Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. *Prim Care Companion J Clin Psychiatry* 2007;9:113–21.
225. Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. *Drugs Aging* 2004;21:453–78.
226. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. *Biol Psychiatry* 2001;49:279–88.
227. Birks J. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev* 2006:CD005593.
228. Hansen RA, Gartlehner G, Kaufer DJ, et al. Drug class review on Alzheimer's drugs: final report. June 2006. (<http://www.ohsu.edu/drugeffectiveness/reports/documents/Alzheimer%20Final%20Report%20Update%201.pdf>).
229. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. *Curr Med Res Opin* 2005;21:1317–27.
230. Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. *J Alzheimers Dis* 2006;10:81–7.
231. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. *Am J Geriatr Psychiatry* 2006;14:704–15.
232. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomized, double-blind, placebo-controlled 6-month study. *J Alzheimers Dis* 2007;11:471–9.
233. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med* 2003;348:1333–41.
234. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 2004;291:317–24.
235. Bird SM, Matthews F, Muniz G. NICE judgment: good law risks bad science. *Lancet Neurol* 2007;6:843–4.
236. Chibnall JT, Tait RC, Harman B, et al. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia. *J Am Geriatr Soc* 2005;53:1921–9.
237. Jewart RD, Green J, Lu CJ, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. *Am J Geriatr Psychiatry* 2005;13:324–8.
238. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med* 2006;355:1525–38.
239. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *JAMA* 2005;293:596–608.
240. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst Rev* 2006:CD003476.
241. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. *J Clin Psychiatry* 2003;64:134–43.
242. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005;294:1934–43.
243. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. *CMAJ* 2007;176:627–32.
244. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. *Ann Intern Med* 2007;146:775–86.
245. Kryzhanovskaya LA, Jeste DV, Young CA, et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. *J Clin Psychiatry* 2006;67:933–45.
246. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. *Neurology* 2006;67:57–63.
247. Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. *Int J Geriatr Psychiatry* 2007;22:890–5.
248. Steinberg M, Tschanz JT, Corcoran C, et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. *Int J Geriatr Psychiatry* 2004;19:19–26.
249. Feldman HH, Van Baelen B, Kavanagh SM, et al. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. *Alzheimer Dis Assoc Disord* 2005;19:29–36.
250. Families care: Alzheimer's caregiving in the United States 2004. Alzheimer's Association and National Alliance for Caregiving, 2004. ([http://www.alz.org/national/documents/report\\_familiescare.pdf](http://www.alz.org/national/documents/report_familiescare.pdf)).
251. Alzheimer's disease facts and figures 2007. Alzheimer's Association, 2007. ([http://www.alz.org/national/documents/report\\_alzfactsfigures2007.pdf](http://www.alz.org/national/documents/report_alzfactsfigures2007.pdf)).
252. Schulz R, Martire LM. Family caregiving of persons with dementia: prevalence, health effects, and support strategies. *Am J Geriatr Psychiatry* 2004;12:240–9.
253. Aneshensel CS, Pearlin LI, Mullan JT, et al. Profiles in caregiving: the unexpected career. San Diego, CA: Academic Press, 1995.
254. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. *J Gen Intern Med* 2001;16:770–8.
255. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. *Alzheimer Dis Assoc Disord* 1997;11(suppl):S35–8.
256. Burns A. The burden of Alzheimer's disease. *Int J Neuropsychopharmacol* 2000;3:31–8.
257. Schulz R, O'Brien AT, Bookwala J, et al. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. *Gerontologist* 1995;35:771–91.
258. Ory MG, Hoffman RR 3rd, Yee JL, et al. Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers. *Gerontologist* 1999;39:177–85.
259. Rabow MW, Hauser JM, Adams J. Supporting family caregivers at the end of life: "they don't know what they don't know". *JAMA* 2004;291:483–91.
260. Haley WE, West CA, Wadley VG, et al. Psychological, social, and health impact of caregiving: a comparison of black and white dementia family caregivers and noncaregivers. *Psychol Aging* 1995;10:540–52.

261. Schulz R, Newsom J, Mittelmark M, et al. Health effects of caregiving: the caregiver health effects study: an ancillary study of the Cardiovascular Health Study. *Ann Behav Med* 1997;19:110–16.
262. Wu H, Wang J, Cacioppo JT, et al. Chronic stress associated with spousal caregiving of patients with Alzheimer's dementia is associated with downregulation of B-lymphocyte GH mRNA. *J Gerontol A Biol Sci Med Sci* 1999;54:M212–15.
263. Shaw WS, Patterson TL, Semple SJ, et al. Longitudinal analysis of multiple indicators of health decline among spousal caregivers. *Ann Behav Med* 1997;19:101–9.
264. Shaw WS, Patterson TL, Ziegler MG, et al. Accelerated risk of hypertensive blood pressure recordings among Alzheimer caregivers. *J Psychosom Res* 1999;46:215–27.
265. Scharlach AE, Runkle MC, Midanik LT, et al. Health conditions and service utilization of adults with elder care responsibilities. *J Aging Health* 1994;6:336–52.
266. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. *JAMA* 1999;282:2215–19.
267. Covinsky KE, Goldman L, Cook EF, et al. The impact of serious illness on patients' families. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. *JAMA* 1994;272:1839–44.
268. Scharlach AE. Caregiving and employment: competing or complementary roles? *Gerontologist* 1994;34:378–85.
269. Stephens MA, Franks MM, Townsend AL. Stress and rewards in women's multiple roles: the case of women in the middle. *Psychol Aging* 1994;9:45–52.
270. Tarlow BJ, Wisniewski SR, Belle SH, et al. Positive aspects of caregiving. *Res Aging* 2004;26:429–53.
271. Kramer BJ. Gain in the caregiving experience: where are we? What next? *Gerontologist* 1997;37:218–32.
272. Motenko AK. The frustrations, gratifications, and well-being of dementia caregivers. *Gerontologist* 1989;29:166–72.
273. Gold DP, Reis MF, Markiewicz D, et al. When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia. *J Am Geriatr Soc* 1995;43:10–16.
274. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. *CMAJ* 1998;159:457–65.
275. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. *JAMA* 2002;287:2090–7.
276. Bullock R. The needs of the caregiver in the long-term treatment of Alzheimer disease. *Alzheimer Dis Assoc Disord* 2004;18:S17–23.
277. Smith GE, Kokmen E, O'Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. *J Am Geriatr Soc* 2000;48:519–25.
278. Rovner BW, German PS, Broadhead J, et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes. *Int Psychogeriatr* 1990;2:13–24.
279. Jones A. The National Nursing Home Survey: 1999 summary. National Center for Health Statistics. *Vital Health Stat* 2002;13. ([http://www.cdc.gov/nchs/data/series/sr\\_13/sr13\\_152.pdf](http://www.cdc.gov/nchs/data/series/sr_13/sr13_152.pdf)).
280. Maas ML, Swanson E, Specht J, et al. Alzheimer's special care units. *Nurs Clin North Am* 1994;29:173–94.
281. Special care units for people with Alzheimer's and other dementias: consumer, education, research, regulatory, and reimbursement issues. Washington, DC: Office of Technology Assessment, 1992.
282. Gruneir A. Dementia special care units in US nursing homes: a current description of distribution and major features. Presented at the Gerontological Society of America, Dallas, Texas, November 2006.
283. Leon J, Cheng C, Alvarez RJ. Trends in special care: changes in SCU from 1991 to 1995 ('95/96 TSC). *J Ment Health Aging* 1997;3:149–68.
284. Coleman EA, Barbaccia JC, Croughan-Minihane MS. Hospitalization rates in nursing home residents with dementia. A pilot study of the impact of a special care unit. *J Am Geriatr Soc* 1990;38:108–12.
285. Chappell NL, Reid RC. Dimensions of care for dementia sufferers in long-term care institutions: are they related to outcomes? *J Gerontol B Psychol Sci Soc Sci* 2000;55:S234–44.
286. Phillips CD, Sloane PD, Hawes C, et al. Effects of residence in Alzheimer disease special care units on functional outcomes. *JAMA* 1997;278:1340–4.
287. Holmes D, Teresi J, Kong J. Service inputs and costs of care related to outcomes among cognitively impaired nursing home residents. *J Ment Health Policy Econ* 2000;3:121–7.
288. Phillips CD, Spry KM, Sloane PD, et al. Use of physical restraints and psychotropic medications in Alzheimer special care units in nursing homes. *Am J Public Health* 2000;90:92–6.
289. Mehr DR, Fries BE. Resource use on Alzheimer's special care units. *Gerontologist* 1995;35:179–84.
290. Gruneir A, Lapane KL, Miller SC, et al. Is dementia special care really special? A new look at an old question. *J Am Geriatr Soc* 2008;56:199–205.
291. The incidence of dementia in Canada. The Canadian Study of Health and Aging Working Group. *Neurology* 2000;55:66–73.
292. Miech RA, Breitner JC, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. *Neurology* 2002;58:209–18.
293. Ganguli M, Dodge HH, Chen P, et al. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. *Neurology* 2000;54:1109–16.
294. Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. *JAMA* 2001;285:739–47.
295. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. *Neurology* 2000;54(suppl):S10–15.
296. Bermejo-Pareja F, Benito-Leon J, Vega S, et al. Incidence and subtypes of dementia in three elderly populations of central Spain. *J Neurol Sci* 2008;264:63–72.
297. Ravaglia G, Forti P, Maioli F, et al. Incidence and etiology of dementia in a large elderly Italian population. *Neurology* 2005;64:1525–30.
298. Ruitenberg A, Ott A, van Swieten JC, et al. Incidence of dementia: does gender make a difference? *Neurobiol Aging* 2001;22:575–80.
299. Li S, Yan F, Li G, et al. Is the dementia rate increasing in Beijing? Prevalence and incidence of dementia 10 years later in an urban elderly population. *Acta Psychiatr Scand* 2007;115:73–9.
300. Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. *Neurology* 2001;57:985–9.

301. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet* 2005;366:2112–17.
302. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. *Neuroepidemiology* 2007;29:125–32.
303. Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. *Neurology* 1992;42:115–19.
304. Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. *Am J Psychiatry* 1995;152:1485–92.
305. Farrag A, Farwiz HM, Khedr EH, et al. Prevalence of Alzheimer's disease and other dementing disorders: Assiut-Upper Egypt study. *Dement Geriatr Cogn Disord* 1998;9:323–8.
306. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. *BMJ* 1995;310:970–3.
307. Gurvit H, Emre M, Tinaz S, et al. The prevalence of dementia in an urban Turkish population. *Am J Alzheimers Dis Other Demen* 2008;23:67–76.
308. Dong MJ, Peng B, Lin XT, et al. The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980–2004 studies. *Age Ageing* 2007;36:619–24.
309. Zhang ZX, Zahner GE, Roman GC, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. *Arch Neurol* 2005;62:447–53.
310. Cullen B, O'Neill B, Evans JJ, et al. A review of screening tests for cognitive impairment. *J Neurol Neurosurg Psychiatry* 2007;78:790–9.
311. O'Connor DW, Pollitt PA, Hyde JB, et al. The reliability and validity of the Mini-Mental State in a British community survey. *J Psychiatr Res* 1989;23:87–96.
312. McDowell I, Kristjansson B, Hill GB, et al. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. *J Clin Epidemiol* 1997;50:377–83.
313. Lorentz WJ, Scanlan JM, Borson S. Brief screening tests for dementia. *Can J Psychiatry* 2002;47:723–33.
314. Fillenbaum GG, Heyman A, Wilkinson WE, et al. Comparison of two screening tests in Alzheimer's disease. The correlation and reliability of the Mini-Mental State Examination and the modified Blessed test. *Arch Neurol* 1987;44:924–7.
315. Stuss DT, Meiran N, Guzman DA, et al. Do long tests yield a more accurate diagnosis of dementia than short tests? A comparison of 5 neuropsychological tests. *Arch Neurol* 1996;53:1033–9.
316. Cerhan JH, Ivnik RJ, Smith GE, et al. Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease. *Clin Neuropsychol* 2002;16:35–42.
317. Lin KN, Wang PN, Chen C, et al. The three-item clock-drawing test: a simplified screening test for Alzheimer's disease. *Eur Neurol* 2003;49:53–8.
318. Sunderland T, Hampel H, Takeda M, et al. Biomarkers in the diagnosis of Alzheimer's disease: are we ready? *J Geriatr Psychiatry Neurol* 2006;19:172–9.
319. Zlokovic BV. Clearing amyloid through the blood-brain barrier. *J Neurochem* 2004;89:807–11.
320. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. *Nat Med* 2002;8:1270–5.
321. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron* 2003;38:547–54.
322. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. *Neurology* 2001;57:801–5.
323. Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. *Ann Neurol* 2001;49:808–10.
324. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 1993;43:1467–72.
325. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. *Ann Neurol* 1996;39:62–70.
326. Mann DM, Iwatsubo T, Pickering-Brown SM, et al. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. *Neurosci Lett* 1997;221:81–4.
327. Schiele F, De Bacquer D, Vincent-Viry M, et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. *Atherosclerosis* 2000;152:475–88.
328. Taddei K, Clarnette R, Gandy SE, et al. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. *Neurosci Lett* 1997;223:29–32.
329. Panza F, Solfrizzi V, Colacicco AM, et al. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. *Neuroreport* 2003;14:605–8.
330. Scacchi R, Gambina G, Ruggeri M, et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. *Neurosci Lett* 1999;259:33–6.
331. Slooter AJ, de Knijff P, Hofman A, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. *Neurosci Lett* 1998;248:21–4.
332. Siest G, Bertrand P, Qin B, et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. *ApoEurope group. Clin Chem Lab Med* 2000;38:721–30.
333. Lehtimäki T, Pirttilä T, Mehta PD, et al. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. *Hum Genet* 1995;95:39–42.
334. Pratico D, Clark CM, Lee VM, et al. Increased 8,12-iso-iPF<sub>2</sub>alpha-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. *Ann Neurol* 2000;48:809–12.
335. Montine TJ, Quinn J, Kaye J, et al. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. *J Mol Neurosci* 2007;33:114–19.
336. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. *Nature* 2002;420:879–84.
337. Tarkowski E, Blennow K, Wallin A, et al. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. *J Clin Immunol* 1999;19:223–30.